STOCKHOLM – September 25, 2025 The shareholders in Umecrine Cognition AB, reg. no. 556698-3655, are hereby given notice to attend an extraordinary general meeting at 2:00 p.m. on Thursday 23 October 2025 at Setterwalls Advokatbyrå's offices at Sturegatan 10 in Stockholm, Sweden. Registration for the meeting commences at 13:30 (CEST).

The complete notice can be found on the company’s website, including additional information concerning power of attorney forms and voting instructions, in Swedish and in Englich.

https://www.umecrinecognition.com/en/extra-general-meeting-october-2025/

About Umecrine Cognition

Umecrine Cognition AB is developing a completely new class of drugs for the treatment of symptoms in the central nervous system related to chronic neuroinflammation – a devastating brain distortion that can lead to severely impaired cognition and fatigue. Chronic neuroinflammation can occur as a result of a number of underlying conditions, including a range of liver diseases as well as neurodegenerative diseases, such as Parkinson’s disease. Results from an internationally acclaimed Phase 2 clinical study indicate that the company's most advanced drug candidate, the GABAA receptor-modulating steroid antagonist golexanolone, normalizes brain signaling and improves cognition and alertness in patients with hepatic encephalopathy. A Phase 2 study is currently ongoing in patients with primary biliary cholangitis. Further, based on intriguing preclinical data, the company is considering pursuing the development of golexanolone in patients with Parkinson’s disease. For more information, visit www.umecrinecognition.com.

For further information, please contact:

Viktor Drvota, CEO, Umecrine Cognition AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@umecrine.se

Attachments

Notice to attend the Extraordinary General Meeting in Umecrine Cognition AB
Umecrine Cognition AB Notice To Attend EGM Sw 250919

Läs mer på MFN